CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
The Golgi apparatus modifies, sorts and packages proteins to be sent to their final destinations, whether that's within or outside of the cell. It's a core function, but little studied in the setting ...
Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of "non-self" tumor cells. However, in chronic ...
A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...
A recent Science study explored how intranuclear metabolic enzymes establish the link between locus-specific epigenetic reprogramming of T cells and nutrient availability. Persistent antigen ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results